Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group    LONN   CH0013841017

LONZA GROUP (LONN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
09/14/2018 09/17/2018 09/18/2018 09/19/2018 09/20/2018 Date
316.3(c) 316.3(c) 317.9(c) 320.9(c) 318.7 Last
206 377 269 836 220 174 332 404 260 838 Volume
+0.16% 0.00% +0.51% +0.94% -0.69% Change
More quotes
Financials (CHF)
Sales 2018 6 076 M
EBIT 2018 1 154 M
Net income 2018 762 M
Debt 2018 3 491 M
Yield 2018 1,02%
Sales 2019 6 465 M
EBIT 2019 1 307 M
Net income 2019 903 M
Debt 2019 2 906 M
Yield 2019 1,15%
P/E ratio 2018 31,87
P/E ratio 2019 26,49
EV / Sales2018 4,51x
EV / Sales2019 4,15x
Capitalization 23 897 M
More Financials
Company
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products.It operates through the Pharma&Biotech and Specialty Ingredients segemnts.The Pharma&Biotech segment deals with the supply of pharmaceutical ingredients and biopharmaceuticals as well as research and... 
More about the company
Surperformance© ratings of Lonza Group
Trading Rating : Investor Rating :
More Ratings
Latest news on LONZA GROUP
09/20LONZA : Expands Ibex TM Solutions to Offer Complete Product Lifecycle Management..
PU
09/20Lonza Expands IbexTM Solutions to Offer Complete Product Lifecycle Management..
TE
09/20LONZA : Expands IbexTM Solutions to Offer Complete Product Lifecycle Management ..
AQ
09/18LONZA : Launches Early-Intermediates Supply Initiative for Small-Molecule APIs
AQ
09/14LONZA : Breaks Ground on Expanded Manufacturing Facility in Greenwood, SC
AQ
09/14LONZA : Launches Early-Intermediates Supply Initiative for Small-Molecule APIs
PU
09/12LONZA : Breaks Ground on Expanded Manufacturing Facility in Greenwood, SC (USA)
PU
09/11LONZA : Releases New Technical Note - 'Construction of a Full-Thickness Skin Mod..
AQ
09/11LONZA : Selects SAP Integrated Business Planning From Camelot ITLab
AQ
09/10LONZA : Selects SAP Integrated Business Planning From Camelot ITLab
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Biotechnology & Medical Research - NEC
MarketScreener Strategies on LONZA GROUP 
LONZA GROUP - 04/20
Technically solid
BUY
LONZA GROUP - 01/24
The stock forcefully approaches new pivot levels
BUY
More Strategies
Latest Tweets
09/20ONLY A DRILL: Bradley County residents received alerts Thursday morning for a..
1
09/14Lonza : Launches Early-Intermediates Supply Initiative for Small-Molecule API.. 
09/03Lonza : Pushing the Boundaries in Automation – First Glimpse of Next-Genera.. 
08/18L-Carnitine - Global Procurement Market Intelligence Report 2018 featuring Aj.. 
07/27$LONN Group AG 1 director sold: A director at Lonza Group Ag sold 3,000 shar.. 
More tweets
Qtime:27
News from SeekingAlpha
07/30Lonza Group AG ADR's (LZAGY) CEO Richard Ridinger on Q2 2018 Results - Earnin.. 
07/25Lonza Group AG ADR 2018 Q2 - Results - Earnings Call Slides 
07/25Lonza Group AG reports 1H results 
06/03Orgenesis, Inc. - Overlooked Stock In The Gene Therapy Contract Development W.. 
05/04Lonza Group AG 2018 Q1 - Results - Earnings Call Slides 
Chart LONZA GROUP
Duration : Period :
Lonza Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 335  CHF
Spread / Average Target 4,4%
EPS Revisions
Managers
NameTitle
Richard Ridinger Chief Executive Officer
Albert M. Baehny Chairman
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
Margot A. Scheltema Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP21.88%24 695
CELLTRION, INC.--.--%34 265
IQVIA HOLDINGS INC27.92%25 370
INCYTE CORPORATION-28.39%14 296
SEATTLE GENETICS, INC.45.25%12 306
NEKTAR THERAPEUTICS-5.07%9 777